patient dropped down 50 pounds; On 2021, the patient experienced covid; On 2021, the patient experienced covid; This is a solicited report received from contactable reporter(s) (Consumer or other non HCP), Program ID: (Not Available). The reporter is the patient. Other Case identifier(s): US-ABBVIE-4225384.  A 75-year-old male patient received BNT162b2 (BNT162B2), as dose number unknown (booster), single (Batch/Lot number: unknown) intramuscular for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation; risankizumab (SKYRIZI [RISANKIZUMAB]), (ongoing) (Lot number: 1172496), subcutaneous for psoriasis. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant) all with onset 2021, outcome "unknown" and all described as "On 2021, the patient experienced covid"; WEIGHT DECREASED (medically significant), outcome "unknown", described as "patient dropped down 50 pounds". The patient underwent the following laboratory tests and procedures: Weight: dropped down to 50 pounds. The action taken for risankizumab was dosage not changed.  The reporter considered "on 2021, the patient experienced covid" and "patient dropped down 50 pounds" related to BNT162b2.  Clinical course: An elderly male with events of non-serious covid, and patient dropped down 50 pounds with risankizumab solution for injection, single-dose prefilled syringe with needle guard. There was no reported medical history. In 2021, the patient experienced covid. On unknown date, the patient experienced patient dropped down 50 pounds. Pfizer/BioNTech was also considered suspect. The patient lost taste buds and had covid one year ago that was in 2021. He dropped down 50 pounds.  Causalities: The reporter's causality for the events of covid and patient dropped down 50 pounds with Risankizumab Solution for Injection was not provided. The reporter's causality for the events of covid and patient dropped down 50 pounds with Pfizer BioNTech covid-19 vaccine (Tozinameran) was reasonable possibility.  Agency's opinion was that the causality for the events of covid and patient dropped down 50 pounds with Pfizer BioNTech covid-19 vaccine (Tozinameran) was not provided. Agency's opinion was that the causality for the event(s) of covid and patient dropped down 50 pounds with Risankizumab solution for injection was not provided.  Assessment Results: Skyrizi-Covid-19, non-health care professional, global introspection, not reported. Skyrizi-Covid-19, market authorization holder (MAH). Pfizer/BioNTech-Covid-19, market authorization holder (MAH). Pfizer/BioNTech-Covid-19, non-health care professional, global introspection, possible. Skyrizi-Weight decreased, market authorization holder (MAH). Skyrizi-Weight decreased, non-health care professional, global introspection, not reported. Pfizer/BioNTech-Weight decreased, market authorization holder (MAH). Pfizer/BioNTech-Weight decreased, non-health care professional, global introspection, possible.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on the available information in the case, the causal association between the reported events suspected Covid-19, drug ineffective, weight decreased and the suspect drug BNT162B2 cannot be excluded.